Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Unknown 2Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Sarcoma, Ewing 2Sarcoma, Clear Cell 2Myoepithelioma 2Liposarcoma, Myxoid 2Histiocytoma, Angiomatoid Fibrous 2Desmoplastic Small Round Cell Tumor 2Chondrosarcoma, Extraskeletal Myxoid 2Sarcoma 1Fibroma 1

Interventions

Cisplatin 517Radiotherapy 378Cyclophosphamide 368Carboplatin 359Capecitabine 342Paclitaxel 337Oxaliplatin 336Gemcitabine 322Docetaxel 317Fluorouracil 291Drug Therapy 277Bevacizumab 249apatinib 247camrelizumab 219Etoposide 201Irinotecan 183Doxorubicin 181Leucovorin 164Dexamethasone 161pembrolizumab 155Neoadjuvant Therapy 146sintilimab 145anlotinib 140Blood Specimen Collection 140Pemetrexed 138Cytarabine 138toripalimab 133Surgical Procedures, Operative 131Radiosurgery 131S 1 (combination) 125

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × seclidemstat × Clear all
NCT03600649 2023-11-21

Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas

Salarius Pharmaceuticals, LLC

Phase 1 Unknown
50 enrolled
Sarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibroma, Myoepithelioma, Sarcoma, Sarcoma, Ewing, Liposarcoma, Myxoid, Sarcoma, Clear Cell, Desmoplastic Small Round Cell Tumor

NCT05266196 2023-08-01

A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)

Salarius Pharmaceuticals, LLC

Phase 1/2 Unknown
10 enrolled
Sarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Myoepithelioma, Sarcoma, Ewing, Liposarcoma, Myxoid, Sarcoma, Clear Cell, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡